Archives des NEWS

Cancer Research: CHF 1.1 Million for Novochizol SA

EPFL and Novochizol SA to collaborate on designing more efficient immunotherapies, with the support of Innosuisse, the Swiss Innovation Agency. The EPFL Laboratory of Biomaterials for Immunoengineering, headed by Prof. Li Tang, and the BioArk Monthey– hosted startup company Novochizol SA possessing a unique chitosan transformation technology, today announced that Innosuisse will co-fund their collaborative …

Cancer Research: CHF 1.1 Million for Novochizol SA Read More »

Biotechgate Digital Partnering is back in November

One of the major events for virtual business development and licensing is back, from November 27th to December 1st, 2023. As a partner of the event, BioArk is pleased to offer Valais life science actors a promo code to participate and enhance their business opportunities! The Biotechgate Digital Partnering virtual event is designed to support …

Biotechgate Digital Partnering is back in November Read More »

Debiopharm invests over 30 million francs in innovation in Martigny

Debiopharm is to build a new Innovation building dedicated to research and development at its Valais site in Martigny. The Lausanne-based biopharmaceutical group will invest CHF 30 million in the project…

Valsynthèse’s name originates from the high-energy value of the chemical reactions involved, necessitating a special skill set for manipulation. | © Valsynthèse

Valsynthèse, 40 years of innovation in the canton of Valais

From dynamite to pharmaceuticals, Valsynthèse, the ‘fine chemistry’ business unit of the Société Suisse des Explosifs, celebrates four decades of steering innovative chemical solutions in Valais.

BioArk’s third building in Monthey has just been inaugurated and is already almost full!

BioArk is on a roll! The Monthey-based technology site, which celebrates its 20th anniversary this year, inaugurated its third building on Friday.

Lonza plan to create 180 jobs in Visp by 2026

The pharmaceutical and biotechnology group Lonza has confirmed the extension of a long-term collaboration with a major global biopharmaceutical partner. The agreement will quadruple current bioconjugation capacity at the Ibex facilities in Visp. The new suites are expected to be operational in 2026 and will generate approximately 180 jobs, according to Lonza.

Australian university partners with Orio Therapeutics spin-out to transform regenerative medicine

The Institute of Life Technologies of the School of Engineering of the HES-SO Valais-Wallis has sealed…

Fighting cancer: HES-SO Valais-Wallis and Debiopharm sign partnership agreement

The Institute of Life Technologies of the School of Engineering of the HES-SO Valais-Wallis has sealed…

Siegfried and Lonza in the world’s top 10 CDMOs!

Two Swiss jewels in the crown of pharmaceutical subcontracting rank 1st and 6th in the world ranking published by Genetic Engineering & Biotechnology News. Proof of a booming sector in our canton.

A test to detect deadly fungal infections is being developed in Valais

GaDia SA, a Valais-based start-up specializing in the development of diagnostic tests, and HES-SO Valais-Wallis are to collaborate on the development of a new-generation rapid test for the detection of fungal infections such as Invasive Pulmonary Aspergillosis (IPA). This research project is supported by Innosuisse, the Swiss innovation promotion agency, to the tune of CHF 350,000.

NEWS

Contact

Start typing and press enter to search